IGF-I bioavailability in congenital isolated growth hormone deficiency
- 13 January 2026
- journal article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 194 (2) , 136-145
Abstract
Background: The Itabaianinha cohort in Brazil carries a homozygous growth hormone-releasing hormone (GHRH) receptor (GHRH-R) gene mutation, causing congenital isolated GH deficiency (GHD). Affected individuals present with severe short stature, central obesity, hypercholesterolemia, and marked reductions in serum GH, IGF-I, and IGFBP 3 concentrations yet show no premature atherosclerosis and maintain a normal lifespan. IGF-I mostly circulates bound to IGFBPs and requires proteolytic cleavage for IGF-I receptor activation. Pregnancy-associated plasma protein A (PAPP-A) is an important IGF-dependent cleavage enzyme, binding to IGFBP 4 and releasing IGF-I. PAPP-A activity is inhibited by stanniocalcin-2 (STC2). The IGFBP 4-STC2-PAPP-A axis (ISPa) has emerged as a key regulator of IGF-I bioactivity. Methods: We evaluated the ISPa in: (1) GHD subjects with homozygous GHRH-R c.57 + 1G→A mutation, (2) heterozygotes (HTZ), and (3) homozygous wild-type controls (HMZ). Parameters from the ISPa were measured at LMU Klinikum, Munich. Additional biochemical parameters were analyzed at the Federal University of Sergipe, Brazil. Results: As expected, GHD subjects had markedly low GH, IGF-I, IGF-II, free IGF-I, and IGFBP 3 (P < .001), while HTZ resembled HMZ subjects. STC2, PAPP-A, and PAPP-A-STC2 complex concentrations did not differ between groups. However, PAPP-A2 and intact IGFBP 4 were higher in the GHD subjects (P < .05 and P < .01). Notably, IGF-I and IGFBP 3 positively correlated with IGF-II, whereas intact IGFBP 4 and PAPP-A2 showed inverse correlations with IGF-I and IGF-II. Conclusion: Our findings suggest altered IGF-I bioavailability regulation via the ISPa in congenital lifetime GHD, leading to increased PAPP-A2 proteolytic activity, reduced PAPP-A enzymatic activity, and reduced sequestration of PAPP-A2 by STC2.Keywords
Funding Information
- Conselho Nacional de Pesquisa (307576/2022-1)
This publication has 55 references indexed in Scilit:
- Skin assessment in congenital untreated isolated GH deficiencyEndocrine, 2024
- Brain morphometry and estimation of aging brain in subjects with congenital untreated isolated GH deficiencyJournal of Endocrinological Investigation, 2024
- Growth hormone and agingReviews in Endocrine and Metabolic Disorders, 2020
- Disruption of the GHRH receptor and its impact on children and adults: The Itabaianinha syndromeReviews in Endocrine and Metabolic Disorders, 2020
- Adult individuals with congenital, untreated, severe isolated growth hormone deficiency have satisfactory muscular functionEndocrine, 2018
- Prognostic relevance and performance characteristics of serum IGFBP‐2 and PAPP‐A in women with breast cancer: a long‐term Danish cohort studyCancer Medicine, 2018
- The role of PAPP-A in the IGF system: location, location, locationJournal of Cell Communication and Signaling, 2015
- Lifetime, untreated isolated GH deficiency due to a GH-releasing hormone receptor mutation has beneficial consequences on bone status in older individuals, and does not influence their abdominal aorta calcificationEndocrine, 2013
- Regulation of insulin-like growth factor binding protein 4 by a specific insulin-like growth factor binding protein 4 proteinase in normal human osteoblast-like cells: Implications in bone cell physiologyJournal of Bone and Mineral Research, 1994
- Premature mortality due to cardiovascular disease in hypopituitarismThe Lancet, 1990